#USA #New York #PAVmed #Duke University #esophageal technology

PAVmed Partners with Duke University to Enhance Esophageal Imaging

In a significant development within the medical technology sector, PAVmed Inc. (Nasdaq: PAVM) has announced its intention to license a revolutionary imaging technology from Duke University. This groundbreaking innovation aims to improve the diagnosis and treatment of esophageal precancer, a condition that affects many patients worldwide.

The technology in question is a multi-modality probe that combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT). Developed by Dr. Adam Wax at Duke University, this tool promises to provide a more efficient alternative to traditional biopsies, which often rely on sampling techniques that can lead to inaccuracies and delays in treatment.

Dr. Nicholas Shaheen, a leading expert on esophageal precancer, emphasizes the potential impact of this technology. According to him, it could transform how clinicians approach diagnostics, directly improving patient outcomes and healthcare efficiency. The current method, primarily based on biopsies, can prolong diagnosis times and lead to significant treatment delays. In contrast, the combined a/LCI + OCT technology offers the possibility of real-time detection, enabling immediate intervention during endoscopic procedures.

Clinical trials led by Drs. Shaheen and Wax have already shown promising results. Early studies indicate that the a/LCI technology can detect precancerous changes in the esophagus with remarkable accuracy. This innovation marks a pivotal shift in the way esophageal dysplasia is diagnosed and treated, offering new hope to those at risk of developing esophageal cancer.

As PAVmed moves forward with this partnership, the company's leadership envisions a surge in the number of patients diagnosed with esophageal precancer. Dr. Lishan Aklog, Chairman and CEO of PAVmed, expressed excitement regarding the commercialization of this technology, predicting that its adoption could streamline patient evaluations while enhancing treatment efficacy.

The letter of intent establishes a pathway for PAVmed to secure exclusive worldwide licensing rights for the intellectual property associated with the a/LCI + OCT technology, contingent upon reaching a definitive agreement. PAVmed’s strategy reflects its commitment to utilizing advanced medical technologies that align with its overarching goal of improving patient care across various healthcare settings.

PAVmed, recognized for its diverse portfolio in the medical field, is poised to play a critical role in advancing the capabilities of endoscopic diagnostics and therapies. Its subsidiary, Lucid Diagnostics, which focuses on cancer-prevention technologies, exemplifies the kind of innovation that PAVmed aims to integrate into its wider operations. This partnership with Duke University reinforces the company’s focus on developing practical solutions for serious medical problems, particularly in the realm of cancer prevention and treatment.

With the successful completion of this venture, PAVmed intends to enhance early detection strategies for esophageal precancer, ultimately aiming to reduce the incidence of esophageal cancer, which remains one of the most challenging malignancies to manage effectively. As medical technology continues to evolve, collaborations like this pave the way for improved clinical outcomes and enhanced patient safety worldwide.

Further updates will be forthcoming as PAVmed progresses towards finalized agreements and develops this exciting new technology, which holds the potential to change the paradigm of care for patients dealing with precancerous conditions.

For ongoing developments regarding PAVmed and their subsidiaries, including Lucid Diagnostics and Veris Health, stay tuned to industry news channels and PAVmed's official communications.